Drug repurposing to target p53 protein family for improved therapy in the relapsed TP53 and EGFR mutated lung cancer

2020/39/B/NZ7/00757

Keywords

Descriptors

  • NZ7_014: Farmacja, farmakoterapia, farmakologia

Panel

NZ7 – Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology

Host institution

Warszawski Uniwersytet Medyczny

Voivodeship: mazowieckie

Other projects carried out by the institution »

Principal investigator (from the host institution)

dr hab. Alicja Elżbieta Chrzanowska

Number of co-investigators in the project: 4

Call

OPUS 20 – announced on 2020-09-15

Amount awarded
2 589 600 PLN
Project start date
2021-12-15
Project end date
2026-12-14
Project duration
60 months (the same as in the proposal)
Project status
Pending project

Project description

Download the project description in a pdf file

Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Information in the final report

Publication in academic press/journals (1)

  1. The Therapeutic Potential of the Restoration of the p53 Protein Family Members in EGFR-Mutated Lung Cancer

    Authors:
    Fregni M, Ciribilli Y, Zawacka-Pankau JE.
    Academic press:
    Int J Mol Sci. (year: 2022, volume: 23(13):7213, pages: 20), Publisher: MDPI
    Status:
    Published
    DOI:
    10.3390/ijms23137213 – link to the publication

« New search

Graphic design and implementation: Jakub Piotrowski